Clinical trials: Leukemia, Acute Myelogenous (AML)
Leukemia, Acute Myelogenous
Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia
This is an open label phase I clinical trial of hydroxychloroquine (HCQ) ,when it is combined with the usual medications for acute myeloid leukemia, mitoxantrone and etoposide.
- Trial name
- NCT02631252
- Testing
- Hydroxychloroquine, Mitoxantrone, Etoposide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Alison Sehgal, MD, MS
Chronic Myeloid Leukemia, Acute Myelogenous Leukemia
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT
The primary objective of this study is to assess the safety and efficacy of performing unrelated stem cell transplants using intravenous busulfan and fludarabine as preparative therapy and tacrolimus plus methotrexate as the GVHD…
- Conditions
- Chronic Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplasia, Acute Lymphocytic Leukemia
- Trial name
- NCT00516152
- Testing
- Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of California, San Francisco
Leukemia, Myeloid
Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia
This Phase 1, clinical study of CC-96191 will explore the safety, tolerability and preliminary biological and clinical activity of CC-96191 as a single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R…
- Trial name
- NCT04789655
- Testing
- CC-96191
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 45 people
- Sponsor
- Celgene
Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
This randomized pilot clinical trial studies how well giving prolonged infusion compared to standard infusion of cefepime hydrochloride works in treating patients with febrile neutropenia.
- Conditions
- Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Burkitt Lymphoma, Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT01484015
- Testing
- cefepime hydrochloride
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Wake Forest University Health Sciences
MDS, AML
Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)
Clofarabine is known to have a stronger anti-tumor effect than Fludarabine and has shown its efficacy in treating aggressive acute leukemias.
- Conditions
- MDS, AML, ALL, BAL
- Trial name
- Cloric (NCT00863148)
- Testing
- Clofarabine in combination with IV busulfan and ATG
- Where
- 6 sites in France
- Volunteers
- 30 people
- Sponsor
- Nantes University Hospital
Chemotherapy Induced Vomiting, Acute Myeloid Leukemia
Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy
The purpose of the study is to find out the efficacy of an anti-emetic drug, Aprepitant as an add-on therapy to prevent vomiting in children and adolescents receiving chemotherapy for leukemia (AML).
- Trial name
- NCT02979548
- Testing
- Aprepitant, Ondansetron, Metoclopramide
- Where
- India
- Volunteers
- 116 people
- Sponsor
- Dr Atul Sharma
Leukemia, Myeloblastic, Acute
Prospective Database for Acute Myeloblastic Leukemia
Prospective Database for Acute Myeloblastic Leukemia
- Trial name
- NCT00538278
- Testing
- Database
- Volunteers
- 2,000 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Acute Myeloid Leukemia (AML), MDS/AML
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project
This is a registry study in adult patients with newly diagnosed or refractory/relapsed myeloid neoplasms Investigator's sites: 80-90 sites in Germany and Austria Estimated duration of observation of an individual patient: 10…
- Trial name
- AMLSG BiO (NCT01252485)
- Where
- 94 sites in Austria, Germany
- Volunteers
- 50,000 people
- Sponsor
- University of Ulm
AML (Acute Myeloid Leukemia)
Matched Sibling Allogenic Stem Cell Transplantation With Adoptive Immunotherapy With Regulatory And Conventional T Cells For High Risk Acute Myeloid Leukemia
The study is a multicentric, interventional study that evaluates the efficacy of allogeneic HLA-matched allo-HSCT consisting of myeloablative conditioning coupled with donor Treg/Tcon adoptive immunotherapy for high-risk AML…
- Trial name
- MATCH-Treg (NCT07552649)
- Testing
- HSCT with Treg/Tcon adoptive immunotherapy
- Where
- 2 sites in Italy
- Volunteers
- 28 people
- Sponsor
- Antonio Pierini
Leukemia, Lymphoma
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, monoclonal antibodies, and radiation therapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00085449
- Testing
- alemtuzumab, cyclosporine, fludarabine phosphate
- Where
- 24 sites in United States
- Sponsor
- Alliance for Clinical Trials in Oncology
Acute Myeloid Leukemia
Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML
Diagnosis: Acute myeloid leukemia refractory to intensive induction chemotherapy; Age ≥ 60 years, no upper age limit; Study drug: low-dose azacitidine, pioglitazone, ATRA; Safety Run-In Phase; randomized Phase II, open-label…
- Trial name
- AML-ViVA (NCT02942758)
- Testing
- low-dose Azacitidine, Pioglitazone, ATRA
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University Hospital Regensburg
Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
This phase II trial studies how well trametinib and protein kinase B (Akt) inhibitor GSK2141795 work in treating patients with acute myeloid leukemia.
- Trial name
- NCT01907815
- Testing
- Akt Inhibitor GSK2141795, Laboratory Biomarker Analysis, Trametinib
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
AML (Acute Myelogenous Leukemia
Correlation of Venetoclax Plasma Concentrations With Toxicity of Hypometilating Agents and Venetoclax Combination for Acute Myeloid Leukemia Patients in Remission.
Venetoclax (VEN) is a potent and selective oral inhibitor of the BCL-2 gene and has shown anti-leukemic activity when used in combination with hypomethylating agents (HMA) in patients with Acute Myeloid Leukemia (AML), both newly…
- Trial name
- VEN-AML (NCT07254312)
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
It is hypothesized that significantly more patients would prefer oral decitabine/cedazuridine to subcutaneous (SC) azacitidine (AZA) due to several factors, including improved treatment convenience, the reduced risk of nosocomial…
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference
- Trial name
- PREFER-HMA (NCT05883956)
- Testing
- Subcutaneous azacitidine, Oral decitabine/cedazuridine
- Where
- 11 sites in Australia, New Zealand
- Volunteers
- 13 people
- Sponsor
- Otsuka Australia Pharmaceutical Pty Ltd
Graft Versus Host Disease, Leukemia
Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. Sometimes the transplanted cells can make an immune response against normal tissues.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00002456
- Testing
- cyclosporine, methotrexate, allogeneic bone marrow transplantation
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia
CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapesd or Refractory Acute Myeloid Leukemia
This is a single center, open-label phase 1/2 study to evaluate the safety and efficacy of targeted CD38 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CD38 positive relapsed or refractory…
- Trial name
- NCT04351022
- Testing
- CART-38
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Refractory Leukemia
Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia
The investigators developed a protocol combining chemotherapy of cladribine, cytarabine and etoposide (CLAGE) as debulking treatment sequential with reduced intensity conditioning regimen Flu-Bu to treat patients with refractory…
- Trial name
- NCT05870995
- Testing
- CALGE-VEN- RIC-conditioning
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Acute Lymphocytic Leukemia, Acute Myeloid Leukemia
Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia
In this pilot study, eligible patients will be treated with 5 days of low dose daunorubicin for one cycle only. Any patient who receives treatment on this protocol will be evaluable for toxicity.
- Trial name
- NCT02914977
- Testing
- Daunorubicin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Tara Lin
Chronic Myeloproliferative Disorders, Leukemia
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
This phase I trial is studying the side effects and best dose of decitabine and FR901228 in treating patients with relapsed or refractory leukemia, myelodysplastic syndromes or myeloproliferative disorders.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00114257
- Testing
- decitabine, romidepsin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
Immunophenotyping and Xist Gene in AML
Acute myeloid leukemia (AML) is a heterogeneous disorder characterized by clonal expansion of myeloid progenitors (blasts) in the bone marrow and peripheral blood.Several studies have reported correlations of aberrantly expressed…
- Trial name
- Xist (NCT04288739)
- Testing
- flow cytometric immunophenotyping, Xist gene by fluorescence insitu hybridization
- Where
- Egypt
- Volunteers
- 65 people
- Sponsor
- Assiut University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.